2022
Gamma Sensory Stimulation at 40Hz for a 6‐month Period Reduces White Matter Atrophy in Alzheimer’s Disease Patients
Da X, Hempel E, Mrozak H, Malchano Z, Vaughan B, Megerian J, Hajos M, Cimenser A. Gamma Sensory Stimulation at 40Hz for a 6‐month Period Reduces White Matter Atrophy in Alzheimer’s Disease Patients. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.063354.Peer-Reviewed Original ResearchWhite matter atrophyMagnetic resonance imagingWhite matter volumeDisease patientsMatter atrophyAD patientsAlzheimer's disease patientsWhite matterMatter volumeOligodendrocyte damageTreatment group participantsSensory stimulationTreatment groupsAdvanced magnetic resonance imagingStructural magnetic resonance imagingAD disease progressionWhite matter degenerationProgression of ADGroup participantsTesla magnetic resonance imagingLarge control groupAuditory-visual stimulationSensory stimulation therapyPlacebo groupClinical presentation
2021
Randomized controlled trial of gamma sensory stimulation treatment maintains functional ability and decreases sleep fragmentation in Alzheimer’s disease patients
Cimenser A, Hempel E, Travers T, Strozewski N, Malchano Z, Hajos M. Randomized controlled trial of gamma sensory stimulation treatment maintains functional ability and decreases sleep fragmentation in Alzheimer’s disease patients. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.056599.Peer-Reviewed Original ResearchADCS-ADL scoresSleep qualityFunctional abilityAlzheimer's diseaseTreatment groupsSham groupDisease patientsAD patientsAlzheimer's Disease Cooperative Study-ActivitiesSensory stimulationSensory stimulation treatmentAD-related pathologySubgroup of patientsDaily Living ScaleImproved sleep qualityModerate Alzheimer's diseaseNew therapeutic approachesAlzheimer's disease patientsSensory stimulation therapyOpposite changesConclusions PatientsMethods PatientsSleep fragmentationClinical trialsTreatment periodEffects of gamma sensory stimulation on cognitive function in Alzheimer’s disease patients
Cimenser A, Konisky A, Shukla M, Mrozak H, Cohen J, Kolin K, Martin K, Boasso A, Hempel E, Malchano Z, Hajos M. Effects of gamma sensory stimulation on cognitive function in Alzheimer’s disease patients. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.056695.Peer-Reviewed Original ResearchMini-Mental State ExaminationSensory stimulationCognitive functionDisease Assessment ScaleCognitive declineSensory stimulation therapyCognitive measuresCognitive abilitiesDisease Rating ScaleCognitive testsDisease patientsAlzheimer's Disease Assessment ScaleAlzheimer's disease patientsSham groupCognitive scoresNeural activityAD-related cognitive declineOnly participantsVisual stimulationAD patientsClinical trialsState ExaminationClinical Dementia Rating SumTreatment groupsAlzheimer's Disease Rating ScaleSafety, feasibility, and adherence of a daily, in‐home gamma sensory stimulation therapy with the Cognito Sensory Stimulation System in Alzheimer’s subjects
Williams M, Cimenser A, Hempel E, Cotter C, Shukla M, Jiang K, Zhang A, Mrozak H, Konisky A, Kwan K, Hajos M, Malchano Z. Safety, feasibility, and adherence of a daily, in‐home gamma sensory stimulation therapy with the Cognito Sensory Stimulation System in Alzheimer’s subjects. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.056480.Peer-Reviewed Original ResearchMean adherenceAD subjectsSerious treatment-emergent adverse eventsTreatment-emergent adverse eventsSensory stimulationEmergent adverse eventsPreclinical AD modelsSelf-administered therapyAdverse event monitoringΒ-amyloid plaquesLong-term safetyModerate AD subjectsSensory stimulation therapyAdverse eventsPhysical examSham participantsNovel therapiesTau tanglesModerate ADStimulation therapyCognition improvementAdherence dataAD modelTreatment sessionsTreatment studiesSensory-Evoked 40-Hz Gamma Oscillation Improves Sleep and Daily Living Activities in Alzheimer’s Disease Patients
Cimenser A, Hempel E, Travers T, Strozewski N, Martin K, Malchano Z, Hajós M. Sensory-Evoked 40-Hz Gamma Oscillation Improves Sleep and Daily Living Activities in Alzheimer’s Disease Patients. Frontiers In Systems Neuroscience 2021, 15: 746859. PMID: 34630050, PMCID: PMC8500065, DOI: 10.3389/fnsys.2021.746859.Peer-Reviewed Original ResearchActive treatment groupHz gamma oscillationsAlzheimer's diseaseSensory stimulationSham groupDisease patientsAD patientsTreatment groupsFunctional abilityAlzheimer's Disease Cooperative Study-ActivitiesGamma oscillationsADCS-ADL scoresDisease-modifying propertiesAdditional clinical benefitBeneficial clinical effectsDaily Living ScaleActive treatment patientsModerate Alzheimer's diseaseAlzheimer's disease patientsNormal neuronal functionDaily living activitiesEyes-closed conditionsSensory stimulation therapyDaily therapyGroup patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply